Label: information for the user
Kaletra 200 mg/50 mg film-coated tablets
lopinavir/ritonavir
Read this label carefully before starting to take this medicine,because it contains important information for you or your child.
Do not take Kaletra with any of the following medicines:
For more information on other medicines that require special precautionssee the list of medicines included in“Other medicines and Kaletra”below.
If you are currently taking any of these medicines, consult your doctor to see if you need to change your treatment for other conditions or your antiretroviral treatment.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Kaletra.
Important information
Inform your doctor if you or your child have or have had
Inform your doctor if you or your child experience
Other medicines and Kaletra
Inform your doctor or pharmacist if you or your child are taking, have taken recently, or may need to take any other medicine.
For more information on other medicines that you should not take if you are taking Kaletrasee the list of medicines included in“Do not take Kaletra with any of the following medicines”above.
Inform your doctor or pharmacist if you or your child are taking, have taken recently, or may need to take other medicines, even those obtained without a prescription.
Medicines for erectile dysfunction (e.g. avanafil, vardenafil, sildenafil, and tadalafil)
Contraceptives
Pregnancy and breastfeeding
Driving and operating machinery
No specific studies have been conducted on the possible effects of Kaletra on the ability to drive and operate machinery. Do not drive or operate machinery if you experience any adverse effects (e.g. nausea) that may affect your ability to do so safely. Consult your doctor.
It is essential to swallow Kaletra tablets whole and not to chew, break, or crush them. |
Follow exactly the administration instructions for this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
How and when to take Kaletra
Use in adults
Use in children
Kaletra is also available in 100 mg/25 mg film-coated tablets. Kaletra oral solution is available for patients who cannot take tablets.
If you or your child take more Kaletra than you should
If you or your child forget to take Kaletra
If you are taking Kaletra twice a day
If you are taking Kaletra once a day
If you or your child stop taking Kaletra
Like all medicines, Kaletra may cause side effects, although not everyone will experience them. It is difficult to distinguish between side effects caused by Kaletra and those of other medicines you are taking at the same time or those resulting from complications of HIV infection.
During HIV treatment, there may be an increase in weight and blood glucose and lipid levels. This may be partly related to recovery of health and lifestyle, and in the case of blood lipids, sometimes to HIV medicines themselves. Your doctor will monitor these changes.
The following side effects have been reported by patients who took this medicine.You should inform your doctor quickly about these or any other symptoms. See your doctor if they persist or worsen.
Very common:may affect more than 1 in 10 people
Common:may affect up to 1 in 10 people
Uncommon:may affect up to 1 in 100 people
Rare:may affect up to 1 in 1,000 people
If you consider that any of the side effects you are experiencing are severe or if you notice any side effect not mentioned in this leaflet, inform your doctor or pharmacist.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet.You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
How should I dispose of unused Kaletra?
Unused medications should not be flushed down the drain or thrown away.
Ask your pharmacist how to dispose of the containers and unused medications. This will help protect the environment.
The active ingredients are lopinavir and ritonavir.
Each Kaletra tablet contains 200 mg of lopinavir and 50 mg of ritonavir.
The other components are:
Tablet
Copovidone, sorbitan laurate, anhydrous colloidal silica, sodium stearyl fumarate.
Capsule coating
Hydroxypropyl cellulose, titanium dioxide, macrogol 400 (polyethylene glycol 400), talc, anhydrous colloidal silica, macrogol 3350 (polyethylene glycol 3350), iron oxide yellow E-172, poloxamer 80.
Appearance of the product and contents of the package
Kaletra coated tablets are yellow in color with a raised impression of (Abbott logo) and “KA”.
Kaletra coated tablets are presented in containers containing 120 tablets (1 plastic bottle with 120 tablets) and multi-containers containing 3 plastic bottles each containing 120 tablets (360 tablets). Multi-containers with blisters of 120 tablets (1 box of 120 tablets or 3 boxes each containing 40 tablets) are also available.
Only some package sizes may be commercially available.
Marketing Authorization Holder:
AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany
Responsible for manufacturing:
AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany
Fournier Laboratories Ireland Limited, Carrigtwohill Business Park, Anngrove, Carrigtwohill, Co. Cork, Ireland
For more information about this medication, please contact the local representative of the marketing authorization holder.
Belgium/Belgique/Belgien AbbVie SA Tel/Tel: +32 10 477811 | Lithuania AbbVie UAB Tel: +370 5 205 3023 | |
???????? ???? ???? ???.: +359 2 90 30 430 | Luxembourg/Luxemburg AbbVie SA Belgium/Belgien Tel/Tel: +32 10 477811 | |
Czech Republic AbbVie s.r.o. Tel: +420 233 098 111 | Hungary AbbVie Kft. Tel.: +36 1 455 8600 | |
Denmark AbbVie A/S Tlf: +45 72 30-20-28 | Malta V.J.Salomone Pharma Limited Tel: +356 22983201 | |
Germany AbbVie Deutschland GmbH & Co. KG Tel: 00800 222843 33 (free of charge) Tel: +49 (0) 611/1720-0 | Netherlands AbbVie B.V. Tel: +31 (0)88 322 2843 | |
Estonia AbbVie Biopharmaceuticals GmbH Eesti filiaal Tel: +372 623 1011 | Norway AbbVie AS Tlf: +47 67 81 80 00 | |
Greece AbbVie ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε. Tel: +30 214 4165 555 | Austria AbbVie GmbH Tel: +43 1 20589-0 | |
Spain AbbVie Spain, S.L.U. Tel: +34 9 1 384 09 10 | Poland AbbVie Polska Sp. z o.o. Tel.: +48 22 372 78 00 | |
France AbbVie Tel: +33 (0)1 45 60 13 00 | Portugal AbbVie, Lda. Tel: +351 (0)21 1908400 | |
Croatia AbbVie d.o.o. Tel: +385 (0)1 5625 501 | Romania AbbVie S.R.L. Tel: +40 21 529 30 35 | |
Ireland AbbVie Limited Tel: +353 (0)1 4287900 | Slovenia AbbVie Biofarmacevtska družba d.o.o. Tel: +386 (1)32 08 060 | |
Island Vistor hf. Tel: +354 535 7000 | Slovakia AbbVie s.r.o. Tel: +421 2 5050 0777 | |
Italy AbbVie S.r.l. Tel: +39 06 928921 | Finland AbbVie Oy Tel: +358 (0)10 2411 200 | |
Cyprus Lifepharma (Z.A.M.) Ltd Tel: +357 22 34 74 40 | Sweden AbbVie AB Tel: +46 (0)8 684 44 600 | |
Lithuania AbbVie SIA Tel: +371 67605000 | United Kingdom AbbVie Ltd Tel: +44 (0)1628 561090 |
Last review date of this leaflet:
The detailed information about this medication is available on the website of the European Medicines Agencyhttp://www.ema.europa.eu
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.